Aurobindo Irbesartan Class Action Settlement -- $2 Million for Contaminated Blood Pressure Drug
By Steve Levine
Published: April 6, 2026
Claim Deadline: June 2, 2026
Settlement Fund: $2,000,000
Class Period: January 1, 2016 -- present
What Is This Settlement About?
Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., and Aurolife Pharma LLC have agreed to a $2,000,000 class action settlement to resolve economic loss claims that the company manufactured and sold irbesartan blood pressure drugs allegedly contaminated with NDEA -- a probable human carcinogen. The settlement is part of the massive multidistrict litigation in the U.S. District Court for the District of New Jersey covering contamination across the entire family of generic sartan blood pressure medications.Irbesartan is a generic prescription drug used to treat high blood pressure (hypertension) and to protect the kidneys in people with type 2 diabetes. It belongs to the angiotensin II receptor blocker (ARB) family of drugs, often called "sartans," which also includes valsartan and losartan. Aurobindo manufactures irbesartan finished drug formulations using its own active pharmaceutical ingredient (API) made through what the company calls its "IC Route of Synthesis."
The lawsuit alleges that this manufacturing process produced API contaminated with NDEA (N-nitrosodiethylamine), a nitrosamine impurity classified by health regulators as a probable human carcinogen. The contamination triggered FDA recalls of multiple sartan medications starting in 2018 and led to consolidated nationwide litigation against the manufacturers. Aurobindo denies all allegations of wrongdoing and denies that the NDEA levels in its irbesartan were harmful or carcinogenic.
This settlement resolves only the economic loss claims -- meaning what consumers and insurers overpaid for a drug that was allegedly defective. It does not cover personal injury or medical monitoring claims, which are being litigated separately in the same MDL. It also does not affect any claims related to losartan or valsartan.
Who Qualifies?
You are a member of the consumer settlement class if you are an individual in the United States who, from January 1, 2016 to the present, paid any amount of money for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo irbesartan API made through Aurobindo's IC Route of Synthesis ("IC ROS Irbesartan").That covers a long class period -- nearly a decade. Aurobindo is one of the largest generic drug manufacturers in the world and supplies irbesartan to many U.S. pharmacies. If you have taken generic irbesartan to manage high blood pressure or diabetic kidney disease at any point since 2016, there is a real chance that some or all of your prescriptions came from Aurobindo.
How to confirm Aurobindo was your manufacturer: Check the label on any old irbesartan pill bottles you still have. The manufacturer is printed on the label. If you no longer have the bottle, your pharmacy can print your full prescription history showing the manufacturer of each fill. Most major pharmacies (CVS, Walgreens, Rite Aid, Walmart, Kroger, Costco, independent pharmacies) will print this for free upon request.
Excluded from the class are Aurobindo itself and its officers, pharmacy benefit managers, most federal and state government entities, personal injury plaintiffs in the MDL, and anyone who timely opts out of the settlement.
How Much Can I Get?
The total settlement fund is $2,000,000. Attorneys' fees (up to one-third, or approximately $666,667), litigation costs, settlement administration expenses, and service awards to the named plaintiffs will be deducted before distribution. The net fund will then be allocated between consumers and third-party payors (like health insurers and welfare funds) according to a method approved by the court.Individual payouts depend on how much you paid for Aurobindo irbesartan during the class period and how many valid claims are filed. Payments will be made pro rata, meaning the more you spent, the larger your share. Because irbesartan is a long-term prescription for blood pressure management, people who took Aurobindo irbesartan for months or years could see meaningful payouts.
Do I Need Proof?
The notice says documentation should be submitted to support your claim if possible, but does not strictly require proof of purchase upfront. Here is the process:• You file your claim form and describe your Aurobindo irbesartan purchases.
• The settlement administrator reviews your claim with attention to fraud and mistaken claims.
• If your documentation is insufficient to approve the claim, the administrator may contact you for proof of purchase from your pharmacy.
• You then provide the requested documentation.
To prevent delays, it is best to include whatever proof you have with your initial claim. Acceptable documentation includes pharmacy receipts, prescription bottle labels showing Aurobindo as the manufacturer, insurance explanation of benefits statements, or a pharmacy-printed prescription history. Your pharmacy can print your prescription history for free.
How Do I File a Claim?
Submit your claim online at SartanMedicationSettlement.com or download a paper claim form and mail it to the settlement administrator at:Sartan Medication Settlement Administrator
P.O. Box 3376
Baton Rouge, LA 70821
Your claim must be submitted online or postmarked by June 2, 2026.
This settlement is part of a broader group of three related settlements involving contaminated sartan blood pressure drugs. If you also purchased Hetero valsartan (sold May -- July 2018) or Vivimed losartan (specific NDCs), you can file claims for those settlements through the same website. See our combined sartan blood pressure drug settlement page for details on all three.
When Will Payments Be Sent?
The final approval hearing is scheduled for June 30, 2026 at 10:00 AM at Courtroom 3D of the U.S. District Court for the District of New Jersey. If the court grants final approval and no appeals are filed, the settlement administrator will begin distributing payments after the effective date defined in the court's final approval order. The exact timing depends on how long claims processing takes after the court approves the settlement.Case Information
Case: In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (MDL No. 2875)
Court: U.S. District Court, District of New Jersey
Judge: Hon. Renee M. Bumb
Defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC
Settlement Fund: $2,000,000
Allegation: Aurobindo irbesartan manufactured using the IC Route of Synthesis was allegedly contaminated with NDEA, a probable human carcinogen
Class Period: January 1, 2016 to present
Who Qualifies: U.S. consumers who paid for Aurobindo IC ROS irbesartan
Claim Deadline: June 2, 2026
Opt-Out Deadline: June 2, 2026
Objection Deadline: June 2, 2026
Final Approval Hearing: June 30, 2026 at 10:00 AM (Courtroom 3D, D.N.J.)
Attorneys' Fees: Up to one-third of the fund (~$666,667)
Class Counsel: Slack Davis Sanger LLP, Honik Law, Kanner & Whiteley LLC
Class Representatives: Jacqueline Harris (Consumer) and MSP Recovery Claims Series LLC (TPP)
Settlement Administrator: Sartan Medication Settlement Administrator, PO Box 3376, Baton Rouge LA 70821
Settlement Website: SartanMedicationSettlement.com
How Do I Find Class Action Settlements?
Find all the latest class actions you can qualify for by getting notified of new lawsuits as soon as they are open to claims:Settlement Website: SartanMedicationSettlement.com
Submit Claim
Official Settlement Notice (PDF)
Sources
• Official Settlement Website -- SartanMedicationSettlement.com• Court-authorized Aurobindo Settlement Notice, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (D.N.J.)
• OpenClassActions -- Combined Sartan Blood Pressure Drug Settlement Overview
• OpenClassActions -- Hetero Valsartan Settlement In-Depth Guide ($11.37M)
• OpenClassActions -- Vivimed Losartan Settlement
Filing Class Action Settlement Claims
Please note that your claim form will be rejected if you submit a settlement claim with any fraudulent information. By providing this information and your sworn statement of its veracity, you agree to do so under the penalty of perjury. If you are not sure whether you qualify, visit the class action administrator's website. OpenClassActions.com is a consumer advocacy and class action news site, and is not a class action administrator or a law firm.
For more class actions keep scrolling below.
DraftKings & FanDuel Addiction Lawsuits
Status: Open
Submit Claim
Kids Playing Roblox - Alleged Abuse
Pre-Qualify Here
Submit Claim
Social Media Addiction - Children
Status: Open
Pre-Qualify
$4.17M RevitaLash Conditioner Settlement
Deadline: April 20, 2026
Submit Claim
$87.5M Beef Prices Settlement
Deadline: June 30, 2026
Submit Claim
Dollar General Bait & Switch Settlement
Deadline: April 13, 2026
Submit Claim
$2.9M Tom's of Maine Toothpaste Settlement
Deadline: July 6, 2026
Submit Claim
$990K Differin Acne Product Settlement
Deadline: May 19, 2026
Submit Claim
Cosequin Dog Supplements Settlement
Deadline: July 21, 2026
Submit Claim
Depo Provera Investigation
Deadline: Pending
Pre-Qualify| Aurobindo Irbesartan Settlement Summary | |
| Status | Open — File Claim Now |
|---|---|
| Claim Deadline | June 2, 2026 |
| Settlement Fund | $2,000,000 |
| Drug | Aurobindo Irbesartan (IC ROS) |
| Contaminant | NDEA (probable carcinogen) |
| Class Period | Jan 1, 2016 – present |
| Final Hearing | June 30, 2026 at 10:00 AM (D.N.J.) |
| Website | Sartan Medication Settlement |
| Related |
All 3 Settlements ($15.26M Combined)
Hetero Valsartan Settlement ($11.37M) Vivimed Losartan Settlement ($1.9M) |